Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02415413
Recruitment Status : Active, not recruiting
First Posted : April 14, 2015
Last Update Posted : February 17, 2021
Sponsor:
Collaborators:
Celgene Corporation
Amgen
Information provided by (Responsible Party):
PETHEMA Foundation

Tracking Information
First Submitted Date  ICMJE March 29, 2015
First Posted Date  ICMJE April 14, 2015
Last Update Posted Date February 17, 2021
Actual Study Start Date  ICMJE May 2015
Actual Primary Completion Date July 5, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 8, 2015)
Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT [ Time Frame: 4 months ]
Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 15, 2021)
  • Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance [ Time Frame: up to 24 weeks ]
    Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance
  • Efficacy- Months to progression free survival [ Time Frame: 60 months ]
    Months to progression free survival
  • Efficacy -Months to overall survival [ Time Frame: 60 months ]
    Months to overall survival
  • Relapse or progression patterns in the group of patients requiring a rescue therapy after june 2020. [ Time Frame: Up to 84 months (from june 2020) ]
    Relapse or progression patterns after first line treatment with KRd->PBPCT->KRd->Rd, in the group of patients requiring a rescue therapy after june 2020.
  • Response rate of rescue therapy in the group of patients requiring a rescue therapy after june 2020. [ Time Frame: Up to 84 months (from june 2020) ]
    Response rate achieved with daratumumab, pomalidomide and dexamethasone (DPd) as rescue therapy, by evaluating all response categories, including immunophenotypic response, sCR, CR, VGPR, PR and SD.
  • Progression Free Survival (PFS) and Overall Survival (OS) from the date of relapse / progression of disease [ Time Frame: Up to 84 months (from june 2020) ]
    PFS and OS from the date of relapse / progression of disease, in the group of patients requiring a rescue therapy.
  • Biological studies in the group of patients requiring a rescue therapy. [ Time Frame: Up to 84 months (from june 2020) ]
    Phenotypic and molecular assessment of the tumor clone that appears in the moment of relapse or disease progression (DP), and comparison against the tumor clone characterized at the moment of inclusion in the first part of the trial.
  • Study of patient immune profile in the group of patients requiring a rescue therapy. [ Time Frame: Up to 84 months (from june 2020) ]
    Assessment of patient immune profile at the moment of inclusion in this modification, and assessment of evolution under DPd treatment.
  • Study of patient immune profile depending on type of relapse, in the group of patients requiring a rescue therapy. [ Time Frame: Up to 84 months (from june 2020) ]
    Assessment of immune profile at the moment of inclusion in patients in biochemical relapse vs. those in symptomatic relapse.
Original Secondary Outcome Measures  ICMJE
 (submitted: April 8, 2015)
  • Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance [ Time Frame: up to 24 weeks ]
    Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance
  • Efficacy- Months to progression free survival [ Time Frame: 60 months ]
    Months to progression free survival
  • Efficacy -Months to overall survival [ Time Frame: 60 months ]
    Months to overall survival
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Official Title  ICMJE A Phase II Multicenter Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy, Followed by High-dose Therapy With Melphalan and Autologous Peripheral Blood Stem Cell Transplantation, Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients ≤ 70 Years Old With Smoldering Multiple Myeloma (SMM) With High Risk of Progression to Symptomatic Myeloma
Brief Summary

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation.

Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months.

Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.

Detailed Description

This clinical trial is a multicenter Phase II study designed to evaluate the efficacy and toxicity of an intensive therapeutic approach in 90 patients with asymptomatic high risk multiple myeloma (SMM).

  1. - Patients will receive an induction treatment consisting of 6 cycles of carfilzomib, lenalidomide and low-dose dexamethasone (KRd): patients will receive carfilzomib 20-36 mg/m2 IV on days 1, 2, 8, 9, 15 and 16; with oral lenalidomide 25 mg daily on days 1-21, subsequently there will be a rest period of a week (from day 22 to day 27). Moreover, oral dexamethasone 40mg daily will be administered weekly (days 1, 8, 15 and 22).
  2. - Following the induction treatment, patients will receive high-dose (200 mg/m2) melphalan-based treatment administered via the intravenous route followed by peripheral blood stem cell transplantation (HDT-ASCT).
  3. - The consolidation treatment will consist of 2 cycles of KRd, with the same doses and scheduled of the induction treatment.
  4. - Maintenance treatment: all patients, without progression to symptomatic multiple myeloma or toxicity requiring discontinuation of the trial, will receive maintenance treatment during 24 cycles.

This maintenance treatment comprises the administration of lenalidomide 10mg on days 1-21, followed by a rest period of 1 week, with the weekly administration of dexamethasone 20mg.

Treatment will be administrated until the end of the maintenance, although patients will continue in the trial.

If biological progression is observed following the discontinuation of the treatment, lenalidomide and dexamethasone will be reinstituted in order to control the disease again. Lenalidomide 10 mg will be administrated on days 1-21 combined with dexamethasone 20mg on days 1, 8, 15 and 22. All patients will be monitored for asymptomatic disease progression and to collect data regarding on overall survival (OS).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Smoldering Multiple Myeloma
Intervention  ICMJE
  • Drug: carfilzomib
  • Drug: Lenalidomide
  • Drug: Dexamethasone
  • Drug: Melphalan
Study Arms  ICMJE Experimental: Carlizomib lenalidomide and low dose dexamethasone

Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.

High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).

Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).

Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone

Interventions:
  • Drug: carfilzomib
  • Drug: Lenalidomide
  • Drug: Dexamethasone
  • Drug: Melphalan
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: April 8, 2015)
90
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2027
Actual Primary Completion Date July 5, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • In the investigator's opinion, the patient must be able to fulfill all the clinical trial requirements.
  • The patient must voluntarily sign the informed consent before any study procedure that is not part of the standard of care for these patients is performed, with the patient's knowledge that he/she may withdraw from the study at any time, without prejudice to his/her future care.
  • The patient must be aged between 18 and 70 years, and eligible to receive high-dose therapy and autologous peripheral blood stem cell transplant.
  • The patient must be diagnosed with smoldering multiple myeloma at high risk of progressing to symptomatic multiple myeloma, or at ultra high risk of progression to symptomatic disease, defined by:
  • smoldering multiple myeloma at high risk of progression to symptomatic disease:

Bone marrow infiltration with plasma cells (PCs) greater than or equal 10% and presence of a monoclonal component, immunoglobulin G (IgG) greater than3 g/dL or IgA greater than 2 g/dL or Bence Jones proteinuria greater than 1 g/24h and absence of lytic lesions, hypercalcemia, renal failure (creatinine less than 2 mg/dL) and anemia (hemoglobin greater than 10 gr/dL or not 2 gr/dL below the lower limit of normal).

Bone marrow infiltration with PCs greater than or equal 10% OR IgG greater than 3 g/dL or immunoglobulin A (IgA) greater than 2 g/dL or Bence Jones proteinuria greater than 1g/24h (but not both together) and always in the absence of lytic lesions, hypercalcemia, renal failure and anemia. These patients may be included in the study if they meet the following additional criteria: A percentage of phenotypically aberrant plasma cells (PCs) within the bone marrow (BM) PC compartment (aPC/ BM PC) greater than or equal 95% and immunoapheresis, defined as a reduction in the levels of 1 or 2 immunoglobulin (Igs) of more than 25% compared with the normal values of the corresponding Ig.

- smoldering multiple myeloma at ultra high risk of progression to symptomatic disease:

Presence of more than 1 focal lesion in MRI (ideally whole body MRI).

Infiltration in the BM equal or higher than 60%.

Ratio of involved/uninvolved serum Friend leukemia cell (FLC) higher than 100.

  • The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status less than 2.
  • The patient must be able to attend the scheduled visits.
  • Women of childbearing potential must have a negative pregnancy test (serum or urine) within the 14 days before the starting the study drug. In addition, sexually active women must agree to use contraceptive methods (hormone contraceptives [oral, injectable or implanted], tubal ligation, intrauterine device, barrier contraceptives with spermicide or have a vasectomised partner) while receiving the study drug. Women of childbearing potential must agree to undergo pregnancy tests every 4 weeks while receiving the study drug (every 14 days for women with irregular menstrual cycles) and 4 weeks after the last dose of study drug.

Exclusion Criteria:

  • Any physical condition or psychiatric disorder that would prevent the patient from signing or understanding the informed consent form.
  • Previous treatment for smoldering multiple myeloma.
  • Pregnancy or breastfeeding.
  • Presence of lytic lesions, anemia, renal failure or hypercalcemia.
  • Any of the following laboratory abnormalities:

Absolute neutrophil count (ANC) less than 1,000/mm3

Platelet count less than 75,000/mm3.

Serum GOT or glutamic pyruvic transaminase (GPT) greater than 3 x upper limit of normal

Serum total bilirubin greater than 2 x upper limit of normal

  • Prior history of neoplasm other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient has been disease-free for > 5 years.
  • Major surgery within 4 weeks before inclusion in the study.
  • Known active infection by human acquired immunodeficiency virus, B or C hepatitis virus.
  • Any investigational drug within 30 days before inclusion in the study.
  • Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrolment.
  • Unstable angina or myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.
  • Uncontrolled hypertension or uncontrolled diabetes.
  • Significant neuropathy (Grades 3?4, or Grade 2 with pain) within 14 days prior to enrollment.
  • Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib).
  • Contraindication to any of the required concomitant drugs or supportive treatments, including intolerance to hydration due to pre-existing pulmonary or cardiac impairment.
  • Left ventricular ejection fraction (LVEF) less than 40
  • Pulmonary hypertension
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02415413
Other Study ID Numbers  ICMJE GEM-CESAR
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party PETHEMA Foundation
Study Sponsor  ICMJE PETHEMA Foundation
Collaborators  ICMJE
  • Celgene Corporation
  • Amgen
Investigators  ICMJE Not Provided
PRS Account PETHEMA Foundation
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP